TradeLink Capital’s Sarepta Therapeutics SRPT Stock Holding History

TradeLink Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,800	Closed	-$334K	–	35
2019 Q1	$334K	Buy	+2,800	New	+$360K	1.78%	24

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TradeLink Capital's SRPT Position: Q2 2019 in Review

TradeLink Capital sold out of Sarepta Therapeutics (SRPT) in Q2 2019, closing a stake of 2,800 shares — an estimated $334K sold.

TradeLink Capital first reported a position in SRPT in Q1 2019 and held it in 1 quarter. The position peaked at $334K in Q1 2019. 365 funds tracked by Wall St. Rank hold SRPT as of Q2 2019.

TradeLink Capital reported no remaining Sarepta Therapeutics position as of Q2 2019 after selling out during the quarter.
TradeLink Capital sold 2,800 Sarepta Therapeutics shares in Q2 2019, an estimated $334K.
TradeLink Capital first reported a position in Sarepta Therapeutics in Q1 2019 and held it in 1 quarter.
TradeLink Capital's Sarepta Therapeutics position peaked at $334K in Q1 2019.
365 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2019.

Based on TradeLink Capital's 13F filing for Q2 2019, filed 31 Jul 2019.